162 related articles for article (PubMed ID: 17390117)
1. [Endogenous anticoagulant therapy for sepsis. Success and failure].
Wiedermann CJ
Internist (Berl); 2007 May; 48(5):537-42, 544. PubMed ID: 17390117
[TBL] [Abstract][Full Text] [Related]
2. [PROWESS--milestone in lowering sepsis mortality].
Reinhart K
Krankenpfl J; 2002; 40(10-12):315. PubMed ID: 12600016
[No Abstract] [Full Text] [Related]
3. Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis.
McCoy C; Matthews SJ
Clin Ther; 2003 Feb; 25(2):396-421. PubMed ID: 12749504
[TBL] [Abstract][Full Text] [Related]
4. Conclusions: drotrecogin alfa (activated)--from bench to practical use at the bedside.
Maki DG
Am J Surg; 2002 Dec; 184(6A Suppl):S47-50. PubMed ID: 12521617
[No Abstract] [Full Text] [Related]
5. Drotrecogin Alfa (Activated): From Bench to Practical Use at the Bedside. Proceedings of meetings of the Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Clinical Evaluation Committee.
Am J Surg; 2002 Dec; 184(6A Suppl):1S-49S. PubMed ID: 12521610
[No Abstract] [Full Text] [Related]
6. Selecting patients with severe sepsis for drotrecogin alfa (activated) therapy.
Sollet JP; Garber GE
Am J Surg; 2002 Dec; 184(6A Suppl):S11-8. PubMed ID: 12521613
[TBL] [Abstract][Full Text] [Related]
7. Risk-benefit analysis for drotrecogin alfa (activated).
Schein RM; Kinasewitz GT
Am J Surg; 2002 Dec; 184(6A Suppl):S25-38. PubMed ID: 12521615
[TBL] [Abstract][Full Text] [Related]
8. [Focal surgery, antibiotic therapy--and then? The role of rhAPC in sepsis].
Spies C; Otter H; Zuckermann-Becker H; Kox WJ
Kongressbd Dtsch Ges Chir Kongr; 2002; 119():834-43. PubMed ID: 12704933
[TBL] [Abstract][Full Text] [Related]
9. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.
Vincent JL; Angus DC; Artigas A; Kalil A; Basson BR; Jamal HH; Johnson G; Bernard GR;
Crit Care Med; 2003 Mar; 31(3):834-40. PubMed ID: 12626993
[TBL] [Abstract][Full Text] [Related]
10. Identifying patients with severe sepsis who should not be treated with drotrecogin alfa (activated).
Morris PE; Light RB; Garber GE
Am J Surg; 2002 Dec; 184(6A Suppl):S19-24. PubMed ID: 12521614
[TBL] [Abstract][Full Text] [Related]
11. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
[TBL] [Abstract][Full Text] [Related]
12. New and emerging therapies for sepsis.
Healy DP
Ann Pharmacother; 2002 Apr; 36(4):648-54. PubMed ID: 11918516
[TBL] [Abstract][Full Text] [Related]
13. Introduction: rationale for using drotrecogin alfa (activated) in patients with severe sepsis.
Dhainaut JF
Am J Surg; 2002 Dec; 184(6A Suppl):S5-10. PubMed ID: 12521612
[No Abstract] [Full Text] [Related]
14. [A new drug which saves lives. Sepsis: chaos in the body--recent aspects of pathophysiology and therapy].
Haas I
Krankenpfl J; 2002; 40(10-12):310-4. PubMed ID: 12600015
[No Abstract] [Full Text] [Related]
15. Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis.
Barie PS; Williams MD; McCollam JS; Bates BM; Qualy RL; Lowry SF; Fry DE;
Am J Surg; 2004 Sep; 188(3):212-20. PubMed ID: 15450822
[TBL] [Abstract][Full Text] [Related]
16. Drotrecogin alfa (activated) for the treatment of meningococcal purpura fulminans.
Bachli EB; Vavricka SR; Walter RB; Leschinger MI; Maggiorini M
Intensive Care Med; 2003 Feb; 29(2):337. PubMed ID: 12594601
[No Abstract] [Full Text] [Related]
17. Drotrecogin alfa (activated) for severe sepsis.
Maglio D
Conn Med; 2002 Mar; 66(3):145-50. PubMed ID: 11957766
[No Abstract] [Full Text] [Related]
18. An updated meta-analysis to understand the variable efficacy of drotrecogin alfa (activated) in severe sepsis and septic shock.
Lai PS; Matteau A; Iddriss A; Hawes JC; Ranieri V; Thompson BT
Minerva Anestesiol; 2013 Jan; 79(1):33-43. PubMed ID: 23174922
[TBL] [Abstract][Full Text] [Related]
19. Severe sepsis.
Bernard G
Am J Surg; 2002 Dec; 184(6A Suppl):S3-4. PubMed ID: 12521611
[No Abstract] [Full Text] [Related]
20. Drotrecogin alfa (activated) for the treatment of severe sepsis and septic shock.
Rice TW; Bernard GR
Am J Med Sci; 2004 Oct; 328(4):205-14. PubMed ID: 15486535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
